Co-administration of ezetimibe and simvastatin in acute myocardial infarction

European Journal of Clinical Investigation

Volumn 37, Issue 5, 2007, Pages 357-363

  Chenot, F ^a   Montant, P F ^a   Marcovitch, O ^a   Blaimont, M ^a   De Meester, A ^a   Descamps, O S ^a  

^a Centre Hospitalier Jolimont Lobbes   (Belgium)

Author keywords

Cardiovascular disease; Ezetimibe; LDL cholesterol; Myocardial infarction; Simvastatin; Triglycerides

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW MOLECULAR WEIGHT HEPARIN; SIMVASTATIN; TICLOPIDINE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HUMAN; LIPID BLOOD LEVEL; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; SIMVASTATIN; TRIGLYCERIDES;

EID: 34247530360     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01797.x     Document Type: Article

References (42)

1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 335 : 1001 9.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S) Group. Lancet 1994 344 : 1383 9.
3. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 : 1349 57.
4. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001 285 : 1711 8.
5. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005 352 : 20 8.
6. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005 352 : 29 38.
7. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004 292 : 1307 16.
8. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000 101 : 207 13.
9. Nissen SE. High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 2004 292 : 1365 7.
10. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004 109 (23 Suppl. 1 III39 43.
11. Davidson MH. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 2005 111 : 2280 1.
12. Rosenson RS, Tangney CC. Beneficial effects of statins. Lancet 1996 348 : 1583.
13. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004 109 (21 Suppl. 1 II42 8.
14. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004 109 (21 Suppl. 1 II18 26.
15. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998 279 : 1643 50.
16. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr., Clark LT, Hunninghake DB et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004 44 : 720 32.
17. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 350 : 1495 504.
18. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352 : 1425 35.
19. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-On to Statin for Effectiveness (EASE) Trial. Mayo Clin Proc 2005 80 : 587 95.
20. Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R et al. Ezetimibe Study Group. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004 26 : 1758 73.
21. Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004 58 : 746 55.
22. Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004 79 : 620 9.
23. Gagne C, Gaudet D, Bruckert E Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002 105 : 2469 75.
24. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005 294 : 2437 45.
25. Rosenson RS. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 2001 1 : 411 20.
26. Sager PT, Capece R, Lipka L, Strony J, Yang B, Suresh R et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 2005 179 : 361 7.
27. Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R et al. Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003 92 : 1414 8.
28. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S et al. Simvastatin versus sezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005 111 : 2356 63.
29. Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, Dimmeler S et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006 27 : 1182 90.
30. Cohen DE, Anania FA, Chalasani N. National Lipid Association Statin Safety Task Force Liver Expert Panel. An assessment of statin safety by hepatologists. Am J Cardiol 2006 97 : 77C 81C.
31. Ronnemaa T, Viikari J, Irjala K, Peltola O. Marked decrease in serum HDL cholesterol level during acute myocardial infarction. Acta Med Scand 1980 207 : 161 6.
32. Rosenson RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993 22 : 933 40.
33. Pfohl M, Schreiber I, Liebich HM, Haring HU, Hoffmeister HM. Upregulation of cholesterol synthesis after acute myocardial infarction - is cholesterol a positive acute phase reactant? Atherosclerosis 1999 142 : 389 93.
34. Henkin Y, Crystal E, Goldberg Y, Friger M, Lorber J, Zuili I et al. Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels. Am J Cardiol 2002 89 : 7 11.
35. Fresco C, Maggioni AP, Signorini S, Merlini PA, Mocarelli P, Fabbri G et al. LATIN Investigators. Variations in lipoprotein levels after myocardial infarction and unstable angina: the LATIN trial. Ital Heart J 2002 3 : 587 92.
36. Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992 41 : 97 101.
37. Stoney CM, West SG, Hughes JW, Lentino LM, Finney ML, Falko J et al. Acute psychological stress reduces plasma triglyceride clearance. Psychophysiology 2002 39 : 80 5.
38. McCann BS, Benjamin GA, Wilkinson CW, Retslaff BM, Russo J, Knopp RH. Plasma lipid concentrations during episodic occupational stress. Ann Behav Med 1999 21 : 103 10.
39. Fogari R, Zoppi A, Pasotti C, Poletti L, Tettamanti F, Malamani G et al. Plasma lipids during chronic antihypertensive therapy with different beta-blockers. J Cardiovasc Pharmacol 1989 14 : S28 32.
40. Wolinsky H. The effects of beta-adrenergic blocking agents on blood lipid levels. Clin Cardiol 1987 10 : 561 6.
41. Chadarevian R, Bruckert E, Dejager S, Presberg P, Turpin G. Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: lack of threshold value. Thromb Res 1999 96 : 175 82.
42. Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004 24 : 1970 5.